PBLS (Parabilis Medicines) Net Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBLS Parabilis Medicines Inc PBLS
10 GF Score
Price $31.50
! 1 Warning Sign
View Full Analysis

What is Parabilis Medicines Net Margin %?

Parabilis Medicines PBLS -4.66% 10 Net Margin % is 0.00% as of Dec. 2025. GuruFocus rates PBLS with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 942 Biotechnology companies, Parabilis Medicines ranks worse than 106157.01% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Parabilis Medicines's Net Income for the six months ended in Dec. 2025 was $-145.89 Mil. Parabilis Medicines's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Parabilis Medicines's net margin for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Parabilis Medicines's Net Margin % or its related term are showing as below:


PBLS's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.445
* Ranked among companies with meaningful Net Margin % only.

Parabilis Medicines  (NAS:PBLS) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Parabilis Medicines Net Margin % Related Terms

Parabilis Medicines Net Margin % Historical Data

* Premium members only.

The historical data trend for Parabilis Medicines's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parabilis Medicines Net Margin % Chart

Parabilis Medicines Annual Data
Trend Dec24 Dec25
Net Margin %
0.00 0.00

Parabilis Medicines Semi-Annual Data
Dec24 Dec25
Net Margin % 0.00 0.00

PBLS vs IDYA, ELVN, BEAM: Net Margin % Comparison

For the Biotechnology subindustry, Parabilis Medicines's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parabilis Medicines Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Parabilis Medicines's Net Margin % distribution charts can be found below:

* The bar in red indicates where Parabilis Medicines's Net Margin % falls into.


PBLS
10GF Score
Parabilis Medicines Inc PBLS
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parabilis Medicines Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Parabilis Medicines's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-145.889/0
= %

Parabilis Medicines's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-145.889/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Parabilis Medicines (PBLS) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Parabilis Medicines and its competitors. According to the industry distribution chart, Parabilis Medicines ranks #999999 out of 942 companies in the Biotechnology industry.
Is Parabilis Medicines' Net Margin % too high?
Parabilis Medicines' current Net Margin % is 0.00%. Based on the distribution chart, Parabilis Medicines ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Parabilis Medicines has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Parabilis Medicines' Net Margin % compare to IDYA and ELVN?
According to the Biotechnology industry distribution chart, Parabilis Medicines ranks #999999 out of 942 companies for Net Margin %. This places Parabilis Medicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Parabilis Medicines and its competitors. Parabilis Medicines's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parabilis Medicines stock overvalued right now?
Parabilis Medicines (PBLS) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Parabilis Medicines' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Parabilis Medicines (PBLS), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parabilis Medicines Business Description

Address 30 Acorn Park Drive, Cambridge Discovery Park, Cambridge, MA, USA, 02140
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score

Get the complete analysis for PBLS

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.50
Price